BRPI0916555A2 - uso de opióides ou miméticos opióides para o tratamento de pacientes com câncer resistente - Google Patents

uso de opióides ou miméticos opióides para o tratamento de pacientes com câncer resistente

Info

Publication number
BRPI0916555A2
BRPI0916555A2 BRPI0916555A BRPI0916555A BRPI0916555A2 BR PI0916555 A2 BRPI0916555 A2 BR PI0916555A2 BR PI0916555 A BRPI0916555 A BR PI0916555A BR PI0916555 A BRPI0916555 A BR PI0916555A BR PI0916555 A2 BRPI0916555 A2 BR PI0916555A2
Authority
BR
Brazil
Prior art keywords
opioids
cancer patients
resistant cancer
treat resistant
opioid mimetics
Prior art date
Application number
BRPI0916555A
Other languages
English (en)
Inventor
Andreas Alt
Claudia Friesen
Erich Miltner
Original Assignee
Universität Ulm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Ulm filed Critical Universität Ulm
Publication of BRPI0916555A2 publication Critical patent/BRPI0916555A2/pt
Publication of BRPI0916555B1 publication Critical patent/BRPI0916555B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0916555-0A 2008-07-31 2009-01-29 Usos de opioides ou miméticos de opioides para tratamento de pacientes com câncer resistente, e combinação farmacêutica BRPI0916555B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08013417.7 2008-07-31
EP08013741.7A EP2149372B1 (en) 2008-07-31 2008-07-31 Use of opioids of the methadone group for the treatment of resistant cancer patients
PCT/EP2009/000584 WO2010012319A1 (en) 2008-07-31 2009-01-29 Use of opioids or opioid mimetics for the treatment of resistant cancer patients

Publications (2)

Publication Number Publication Date
BRPI0916555A2 true BRPI0916555A2 (pt) 2015-11-10
BRPI0916555B1 BRPI0916555B1 (pt) 2021-06-29

Family

ID=40011012

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916555-0A BRPI0916555B1 (pt) 2008-07-31 2009-01-29 Usos de opioides ou miméticos de opioides para tratamento de pacientes com câncer resistente, e combinação farmacêutica

Country Status (13)

Country Link
US (1) US8901175B2 (pt)
EP (2) EP2149372B1 (pt)
JP (1) JP5804945B2 (pt)
CN (1) CN102159212B (pt)
BR (1) BRPI0916555B1 (pt)
CA (1) CA2732497C (pt)
DK (2) DK2149372T3 (pt)
ES (2) ES2482168T3 (pt)
HU (1) HUE031337T2 (pt)
PL (2) PL2149372T3 (pt)
PT (2) PT2149372E (pt)
RU (1) RU2520636C2 (pt)
WO (1) WO2010012319A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
DK2716291T3 (da) 2012-10-08 2020-03-02 Univ Ulm Kombination af opioider og anticancer-lægemidler til cancerbehandling
EP3697393A4 (en) * 2017-10-20 2021-10-13 Purdue Pharma LP PHARMACEUTICAL DOSAGE FORMS
WO2019197015A1 (en) 2018-04-09 2019-10-17 Peter Truog Composition comprising 4-phenylbutyric acid derivatives & opioids
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
WO2020239948A1 (en) 2019-05-28 2020-12-03 Isanas Ag A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173486A (en) * 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
AU2006247803B2 (en) * 2005-05-13 2011-12-22 Novartis Ag Methods for treating drug resistant cancer

Also Published As

Publication number Publication date
JP5804945B2 (ja) 2015-11-04
ES2596363T3 (es) 2017-01-09
CA2732497A1 (en) 2010-02-04
EP2320900B1 (en) 2016-07-06
US20110270011A1 (en) 2011-11-03
EP2149372B1 (en) 2014-04-02
PL2149372T3 (pl) 2015-03-31
RU2520636C2 (ru) 2014-06-27
PT2320900T (pt) 2016-10-13
DK2320900T3 (en) 2016-10-24
EP2320900A1 (en) 2011-05-18
JP2011529454A (ja) 2011-12-08
HUE031337T2 (hu) 2017-07-28
EP2149372A1 (en) 2010-02-03
DK2149372T3 (da) 2014-07-07
PL2320900T3 (pl) 2017-01-31
RU2011107280A (ru) 2012-09-10
CN102159212A (zh) 2011-08-17
ES2482168T3 (es) 2014-08-01
CN102159212B (zh) 2015-09-16
CA2732497C (en) 2017-01-17
BRPI0916555B1 (pt) 2021-06-29
US8901175B2 (en) 2014-12-02
PT2149372E (pt) 2014-07-25
WO2010012319A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
FR21C1062I1 (fr) Traitement combiné de tumeurs exprimant la cd38
BRPI0807487A2 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BRPI0908127A2 (pt) Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
FR2951637B1 (fr) Table pour massages de personnes allongees ou assises.
BRPI0719210A2 (pt) Uso de compostos espiro-oxindol como agentes terapêuticos
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI0819821A2 (pt) Preparação e uso de polianilinas para tratamento de água
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0912683A2 (pt) tratamento de tumores metastáticos
BR112013013898A2 (pt) compostos de pirimidinona para o uso no tratamento de doenças ou condições mediadas por lp-pla2
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
BRPI0910780A2 (pt) uso de antagonistas de opióides para o tratamento da retenção urinária
BRPI0916555A2 (pt) uso de opióides ou miméticos opióides para o tratamento de pacientes com câncer resistente
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BR112012005774B8 (pt) uso de um inibidor de quinase antiangiogênico no tratamento de câncer
BRPI0916043A2 (pt) composição farmacêutica e alimento funcional para prevenir ou tratar câncer
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.